Shares of The Medicines Co. (NASDAQ:MDCO) saw an uptick in trading volume on Wednesday . 882,247 shares were traded during mid-day trading, an increase of 32% from the previous session’s volume of 669,942 shares.The stock last traded at $39.12 and had previously closed at $39.58.

Several brokerages recently issued reports on MDCO. Jefferies Group reissued a “buy” rating on shares of The Medicines in a research note on Saturday, May 14th. Cowen and Company began coverage on The Medicines in a research note on Thursday, May 5th. They issued an “outperform” rating and a $45.00 price objective on the stock. Zacks Investment Research raised The Medicines from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Royal Bank Of Canada reissued a “buy” rating on shares of The Medicines in a research note on Tuesday, July 12th. Finally, Chardan Capital reissued a “buy” rating on shares of The Medicines in a research note on Thursday, June 2nd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $47.33.

The company’s 50 day moving average is $37.00 and its 200 day moving average is $34.78. The firm’s market capitalization is $2.72 billion.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, July 27th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.54. The firm had revenue of $54.70 million for the quarter, compared to analysts’ expectations of $41.93 million. The firm’s quarterly revenue was down 26.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.65) EPS. Equities research analysts expect that The Medicines Co. will post ($1.36) earnings per share for the current year.

In other news, EVP Christopher T. Cox purchased 53,340 shares of The Medicines stock in a transaction dated Tuesday, June 7th. The shares were purchased at an average price of $37.55 per share, with a total value of $2,002,917.00. Following the transaction, the executive vice president now owns 20,800 shares in the company, valued at $781,040. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Hiroaki Shigeta sold 3,849 shares of The Medicines stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $38.50, for a total transaction of $148,186.50. Following the sale, the director now directly owns 23,547 shares in the company, valued at approximately $906,559.50. The disclosure for this sale can be found here.

Other hedge funds recently bought and sold shares of the company. RS Investment Management Co. LLC increased its stake in The Medicines by 76.1% in the fourth quarter. RS Investment Management Co. LLC now owns 1,198,632 shares of the company’s stock valued at $44,757,000 after buying an additional 517,940 shares during the period. Dimensional Fund Advisors LP increased its stake in The Medicines by 5.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,895,993 shares of the company’s stock valued at $70,796,000 after buying an additional 105,865 shares during the period. Jennison Associates LLC increased its stake in The Medicines by 2.3% in the fourth quarter. Jennison Associates LLC now owns 920,383 shares of the company’s stock valued at $34,367,000 after buying an additional 21,068 shares during the period. US Bancorp DE increased its stake in The Medicines by 20.1% in the fourth quarter. US Bancorp DE now owns 28,684 shares of the company’s stock valued at $1,071,000 after buying an additional 4,794 shares during the period. Finally, Principal Financial Group Inc. increased its stake in The Medicines by 8.5% in the fourth quarter. Principal Financial Group Inc. now owns 468,857 shares of the company’s stock valued at $17,507,000 after buying an additional 36,761 shares during the period.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.